<DOC>
	<DOCNO>NCT02589665</DOCNO>
	<brief_summary>The main purpose study test hypothesis treatment LY3074828 superior placebo provide clinical benefit participant moderate severe ulcerative colitis ( UC ) . This study also investigate body process drug .</brief_summary>
	<brief_title>A Study LY3074828 Participants With Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Have moderate severe active UC define Mayo score 6 12 endoscopic subscore ≥2 within 14 day first dose study treatment ( note : partial Mayo score least 4 eligibility criterion must meet endoscopy perform study procedure ) Have evidence UC extend proximal rectum ( ≥15 centimeter [ cm ] involve colon ) Uptodate colorectal cancer surveillance ( perform accord local standard ) , subject family history colorectal cancer , personal history increase colorectal cancer risk , age &gt; 50 year , know risk factor Participants must either : naive biologic therapy ( eg , tumor necrosis factor [ TNF ] antagonists vedolizumab ) least 1 follow : inadequate response failure tolerate current treatment oral intravenous corticosteroid immunomodulators ( 6mercaptopurine azathioprine ) history corticosteroid dependence ( inability successfully taper corticosteroid without return UC ) OR receive treatment 1 biologic agent ( eg , TNF antagonists vedolizumab ) dose approved treatment UC document history failure respond tolerate treatment Have diagnose indeterminate colitis , proctitis ( distal disease involve rectum ; le 15 cm anal verge ) Crohn 's Disease Have surgery treatment UC likely require surgery UC study Have receive following treatment UC : cyclosporine thalidomide within 30 day screen , corticosteroid enema , corticosteroid suppository , topical treatment 5aminosalicyclic acid within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>IL-23 antibody</keyword>
</DOC>